[
    "2 (d), 132.03 (s), 134.99 (s), 135.97 (s), 137.42 (s), 160.82 (s), 197.15 (s).</p>Antrocamol LT2 was a transparent aqueous product, the molecular formula was determined as: C<sub>26</sub>H<sub>40</sub>O<sub>6</sub>; 4-acetoxy-5-[9-hydroxy-3,7,11-trimethyldodeca-2,6,10-trienyl]-2,3-dimethoxy-6-methyl-cyclohex-2-enone; molecular weight: 448.</p>1H-NMR Spectral Data of Antrocamol LT2: <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): \u25a1 1.18 (3H, d, J=7.2 Hz), 1.54 (3H, s), 1.64 (3H, s), 1.67 (3H, s), 1.69 (3H, s), 1.72 (1H, m), 1.80-2.40 (8H), 2.50 (1H, dq, J=11.6, 7.2 Hz), 3.65 (3H, s), 3.98 (3H, s), 4.36 (1H, m), 5.10 (1H, t, J=6.8 Hz), 5.12 (1H, d, J=8.0 Hz), 5.20 (1H, t, J=6.4 Hz), 5.72 (1H, t, J=3.2 Hz); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>): \u25a1\u25a1 12.80 (q), 15.96 (q), 16.09 (q), 18.14 (q), 20.93 (q), 25.72 (q), 26.19 (t), 26.76 (t), 39.47 (t), 41.25 (d), 42.98 (d), 48.12 (t), 59.65 (q), 60.67 (q), 65.53 (d), 68.98 (d), 120.74 (d), 127.42 (d), 128.25 (d), 131.74 (s), 134.70 (s), 137.31 (s), 137.56 (s), 158.21 (s), 169.73 (s), 196.84 (s).</p>TABLE 9MDA-MB-MDCKCT26A549HepG2PC3DU-145231MCF-7\u03bcg/ml\u03bcg/ml\u03bcg/ml\u03bcg/ml\u03bcg/ml\u03bcg/ml\u03bcg/ml\u03bcg/mlANCA-E&gt;2001010101120.28 \u00b1 1.21&gt;100ANCA-E-D1001110.10.130.72 \u00b1 0.9735.03 \u00b1 4.32ANCA-E-250.10.10.10.10.126.53 \u00b1 1.8230.85 \u00b1 1.19D-3Antrocamol&gt;100.070 \u00b1 0.0060.093 \u00b1 0.0030.014 \u00b1 0.0010.057 \u00b1 0.0020.057 \u00b1 0.009\u20020.98 \u00b1 0.05\u20020.99 \u00b1 0.08LT1Antrocamol&gt;100.80 \u00b1 0.031.06 \u00b1 0.220.59 \u00b1 0.020.69 \u00b1 0.060.91 \u00b1 0.08\u20021.03 \u00b1 0.05\u20020.95 \u00b1 0.11LT2</p>The half maximal inhibitory concentration (IC50) is a measure of the effectiveness of a compound in inhibiting biological or biochemical function. This quantitative measure indicates how much of a particular drug or other substance (inhibitor) is needed to inhibit a given biological process (e.g. cell apoptosis-inducing activity of a compound) by half. As shown in table 9, novel compounds Antrocamol LT1, Antrocamol LT2, and extracts of ANCA-E, ANCA-E-D and ANCA-E-D-3 had a predominant anti cancer activity for various cancers, such as lung cancer, colon cancer, prostate cancer, liver cancer and breast cancer. In the future, based on the present invention, these novel compounds and extracts can be further developed to anti cancer drugs.</p>All of the references cited herein are incorporated by reference in their entirety.</p>The foregoing description of the exemplary embodiments of the invention has been presented only for the purposes of illustration and description and is not intended to be exhaustive or to limit the invention to the precise forms disclosed. Many modifications and variations are possible in light of the above teaching.</p>The embodiments and examples were chosen and described in order to explain the principles of the invention and their practical application so as to enable others skilled in the art to utilize the invention and various embodiments and with various modifications as are suited to the particular use contemplated. Alternative embodiments will become apparent to those skilled in the art to"
]